$1.15
00.00%
At Close: -
$1.18
0.032.70%
After Hours: 7:00 AM EDT
15 minutes delayed
Comments
Loading...
Cyclo Therapeutics
CYTHNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Cyclo Therapeutics (NASDAQ:CYTH) Stock, Analyst Ratings, Price Targets, Forecasts
Cyclo Therapeutics Inc has a consensus price target of $3.2 based on the ratings of 3 analysts. The high is $4 issued by Maxim Group on September 27, 2023. The low is $2.6 issued by Ascendiant Capital on April 22, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Ascendiant Capital on May 31, 2024, May 1, 2024, and April 22, 2024, respectively. With an average price target of $2.87 between HC Wainwright & Co., HC Wainwright & Co., and Ascendiant Capital, there's an implied 142.73% upside for Cyclo Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Ascendiant Capital
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Cyclo Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/31/2024 | Buy Now | 154.02% | HC Wainwright & Co. | Swayampakula Ramakanth | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2024 | Buy Now | 154.02% | HC Wainwright & Co. | Swayampakula Ramakanth | → $3 | Initiates | → Buy | Get Alert |
| 04/22/2024 | Buy Now | 120.15% | Ascendiant Capital | Lucas Ward | → $2.6 | Initiates | → Buy | Get Alert |
| 09/27/2023 | Buy Now | 238.7% | Maxim Group | Jason McCarthy | → $4 | Upgrade | Hold → Buy | Get Alert |
| 03/21/2023 | Buy Now | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for Cyclo Therapeutics (CYTH) stock?
The latest price target for Cyclo Therapeutics (NASDAQ:CYTH) was reported by HC Wainwright & Co. on May 31, 2024. The analyst firm set a price target for $3.00 expecting CYTH to rise to within 12 months (a possible 154.02% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cyclo Therapeutics (CYTH)?
The latest analyst rating for Cyclo Therapeutics (NASDAQ:CYTH) was provided by HC Wainwright & Co., and Cyclo Therapeutics reiterated their buy rating.
When was the last upgrade for Cyclo Therapeutics (CYTH)?
The last upgrade for Cyclo Therapeutics Inc happened on September 27, 2023 when Maxim Group raised their price target to $4. Maxim Group previously had a hold for Cyclo Therapeutics Inc.
When was the last downgrade for Cyclo Therapeutics (CYTH)?
The last downgrade for Cyclo Therapeutics Inc happened on March 21, 2023 when Maxim Group changed their price target from N/A to N/A for Cyclo Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Cyclo Therapeutics (CYTH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cyclo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cyclo Therapeutics was filed on May 31, 2024 so you should expect the next rating to be made available sometime around May 31, 2025.
Is the Analyst Rating Cyclo Therapeutics (CYTH) correct?
While ratings are subjective and will change, the latest Cyclo Therapeutics (CYTH) rating was a reiterated with a price target of $3.00 to $3.00. The current price Cyclo Therapeutics (CYTH) is trading at is $1.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.